We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly has begun enrolling patients for a phase 3 trial of its rheumatoid arthritis treatment Olumiant (baricitinib) for hospitalized COVID-19 patients. Read More
Gilead Sciences has signed four more non-exclusive licensing agreements with generic drugmakers to make remdesivir available to COVID-19 patients in low-income countries. Read More
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance to provide up to 400 million doses of its COVID-19 vaccine at no profit starting by the end of the year. Read More
The Walter Reed Army Institute of Research has chosen a lead COVID-19 vaccine candidate from more than two dozen prototypes and plans to begin clinical trials later this year. Read More
The European Investment Bank is making available up to $113 million in financing for BioNTech’s BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity for it in Europe. Read More
Maryland-based Emergent BioSolutions has signed an $87 million contract with AstraZeneca to support development and production of the UK company’s COVID-19 vaccine, one of the leading candidates in the global race for an effective product. Read More
“Manufacturers must be able to demonstrate how they have met the high levels of safety and performance expected from all medical devices,” the agency said. Read More
Fujifilm said it plans to invest $928 million to double production capacity at its biologics manufacturing facility in Denmark to supply bulk drug substances for future COVID-19 therapies and other products. Read More